About
Your partner in Engineered Affinity
Nemdx pioneers a revolutionary approach to manipulating RNA beyond nature’s blueprint. Our innovation reshapes RNA-protein interactions to advance medical science and biotechnology.
At Nemdx, we’re on a mission to redefine the frontiers of Therapeutics, Drug Diagnostics Co-Development and Disease Diagnostics.
Our innovative binding approach enables a deeper understanding of the biochemical dynamics of proteins in complex heterogeneous diseases.
We started with neurodegenerative disease like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD), where we aim to make significant strides in understanding the heterogenous nature of disease, providing early diagnosis and conceiving treatments.
A Collective of Visionary Innovators and Tech Experts Committed to Pioneering Breakthroughs in RNA Science and Transforming the Future of Biotechnology.
Nemdx’s Innovation:
Our technologies optimize the biochemical binding of molecules, resulting in tailored assays that outperform traditional methods. By integrating 3D polypeptide structural information and amino acid-nucleotide interaction data, our assays offer higher affinity, target specificity, and binding options compared to antibodies and aptamers.
Application Areas:
Nemdx’s technology has a broad range of applications, including neurodegenerative diseases, cancer research, infectious diseases, and other pharmaceutical studies. Our versatile approach enables precise and reliable quantification of compounds, contributing to faster product development.
NEMDX
Contact Us
NEMDX
Locations
- Headquarters: Boston, MA, USA
- R&D Lab: Discovery Park, Sandwich, UK
- Commercial Lab: Framingham, MA, USA